Volume 10,Issue 3
New initiatives for transforming clinical research in Korea
Korea has continuously sought to improve its regulatory environment for clinical trials and has invested heavily in clinical trial infrastructure and technology since the early 2000’s. A strategic investment through the Korea National Enterprise for Clinical Trials (KoNECT) program began in 2007 and grew to encompass a network of regional clinical trial centers to promote clinical trial capabilities and human resource development. In early 2014, KoNECT became a permanent organization focused on the advancement of the country's clinical trial industry. This was followed by the establishment of the Korea Clinical Trials Global Initiative (KCGI) and the KoNECT Collaboration Center for global clinical trials (KCC). KCGI and KCC are now at the forefront of KoNECT’s efforts to promote higher operational efficiency in the country’s clinical trials. These new initiatives in clinical research are undertaking multichannel approaches to pursue a cohesive international collaboration model between government, industry and academia for the development of new treatments and improved patient care.
1. Shin, S. (2011). The current status and policy of early stage clinical trials in Korea. Clin Eval, 39(2), 367–375.
2. Korea National Enterprise for Clinical Trials (KoNECT) home page. Retrieved December 14, 2015, from <www.konect.or.kr>
3. Khaleel, S. (2014). South Korea: Sprinting clinical trial development. Clinical Leader. Retrieved December 14, 2015, from <http://www.clinicalleader.com/doc/south-korea-sprinting-clinical-trial-development-0001>
4. Berthier, M., & McMillan, D. (2015). Making feasibility more reliable in clinical trials. epm Magazine. Retrieved October 17, 2015, from <http://www.epmmagazine.com/opinion/making-feasibility-more-reliable-in-clinical-trials/>
5. Miseta, E. (2015). Proper feasibility planning is critical for clinical trial success. Clinical Leader. Retrieved October 17, 2015, from <http://www.clinicalleader.com/doc/proper-feasibility-planning-is-critical-for-clinical-trial-success-0001>
6. Gehring, M., Taylor, R. S., Mellody, M., et al. (2013). Factors influencing clinical trial site selection in Europe: The survey of attitudes towards trial sites in Europe (the SAT-EU Study). BMJ Open, 3(11), e002957. <http://dx.doi.org/10.1136/bmjopen-2013-002957>
7. Ayalew, K. (2013). FDA perspective on international clinical trials. U.S. Food and Drug Administration. Retrieved October 14, 2015, from <http://www.fda.gov/downloads/Training/ClinicalInvestigatorTrainingCourse/UCM378499.pdf>
8. KoNECT Collaboration Center home page. Retrieved December 14, 2015, from <http://kcc.konect.or.kr/>